Atara Biotherapeutics shares rise on MS drug study results
Atara Biotherapeutics Inc. shares climbed in the extended session Thursday after the biotech drug developer reported positive results from an early stage clinical trial of its multiple sclerosis drug. Atara shares rose 8.7% to $20.55 after hours. The company said a Phase I trial showed its ATA188 drug was well tolerated in MS patients and that half experienced improvements in their symptoms. MS is a disease that attacks the insulation of nerve fibers causing disruptions to electrical impulses traveling within them.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.